{
    "Rank": 132,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00244933",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "2597"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "P30CA022453",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA022453"
                        },
                        {
                            "SecondaryId": "WSU-C-2597",
                            "SecondaryIdType": "Other Identifier",
                            "SecondaryIdDomain": "Barbara Ann Karmanos Cancer Institute"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Barbara Ann Karmanos Cancer Institute",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer",
                "OfficialTitle": "Phase II Trial of Gemcitabine and Genistein in Metastatic Breast Cancer Patients With Biomarker Assays"
            },
            "StatusModule": {
                "StatusVerifiedDate": "May 2023",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "February 2004"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "November 2008",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2009",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "October 25, 2005",
                "StudyFirstSubmitQCDate": "October 25, 2005",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "October 27, 2005",
                    "StudyFirstPostDateType": "Estimate"
                },
                "ResultsFirstSubmitDate": "January 12, 2015",
                "ResultsFirstSubmitQCDate": "January 30, 2015",
                "ResultsFirstPostDateStruct": {
                    "ResultsFirstPostDate": "February 2, 2015",
                    "ResultsFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "May 22, 2023",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 22, 2023",
                    "LastUpdatePostDateType": "Actual"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyType": "Principal Investigator",
                    "ResponsiblePartyInvestigatorFullName": "Lawrence E. Flaherty",
                    "ResponsiblePartyInvestigatorTitle": "Investigator",
                    "ResponsiblePartyInvestigatorAffiliation": "Barbara Ann Karmanos Cancer Institute"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Barbara Ann Karmanos Cancer Institute",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine hydrochloride together with genistein may kill more tumor cells.\n\nPURPOSE: This phase II trial is studying how well giving gemcitabine hydrochloride together with genistein works in treating women with stage IV breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nPrimary\n\nDetermine the objective response rate in patients with stage IV breast cancer treated with gemcitabine hydrochloride and genistein.\n\nSecondary\n\nDetermine the duration of response and survival of patients treated with this regimen.\nDetermine the time to disease progression in patients treated with this regimen.\nDetermine the quantitative and qualitative toxic effects of this regimen in these patients.\nCorrelate plasma genistein levels with response in patients treated with this regimen.\n\nOUTLINE: Patients receive oral genistein once daily on days -7 to 1. Patients also receive gemcitabine hydrochloride IV on days 1 and 8 and oral genistein once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nPROJECTED ACCRUAL: A total of 36 patients will be accrued for this study."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV breast cancer",
                        "recurrent breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 2"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "19",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "ArmGroupList": {
                    "ArmGroup": [
                        {
                            "ArmGroupLabel": "Gemcitabine, genistein (Novasoy), Tumor biopsy",
                            "ArmGroupType": "Experimental",
                            "ArmGroupDescription": "Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.",
                            "ArmGroupInterventionList": {
                                "ArmGroupInterventionName": [
                                    "Dietary Supplement: genistein",
                                    "Drug: gemcitabine",
                                    "Procedure: Tumor biopsy"
                                ]
                            }
                        }
                    ]
                },
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Dietary Supplement",
                            "InterventionName": "genistein",
                            "InterventionDescription": "Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Gemcitabine, genistein (Novasoy), Tumor biopsy"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Novasoy"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "gemcitabine",
                            "InterventionDescription": "Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Gemcitabine, genistein (Novasoy), Tumor biopsy"
                                ]
                            },
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "Gemcitabine hydrochloride",
                                    "Gemzar\u00ae"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "Tumor biopsy",
                            "InterventionDescription": "Biopsy of tumor prior to dose of genistein (Novasoy)",
                            "InterventionArmGroupLabelList": {
                                "InterventionArmGroupLabel": [
                                    "Gemcitabine, genistein (Novasoy), Tumor biopsy"
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Objective Response Rate by RECIST Criteria Following",
                            "PrimaryOutcomeDescription": "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
                            "PrimaryOutcomeTimeFrame": "every 2 courses until disease progression or death, up to 24 weeks"
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically or cytologically confirmed breast cancer\n\nStage IV disease\nClinical and/or radiological evidence of metastatic disease\n\nMeasurable disease\n\nPrior radiotherapy allowed provided there is \u2265 1 measurable disease site outside the radiation field\n\nNo active CNS metastases\n\nPreviously treated CNS metastases allowed provided disease is stable for \u2265 3 months without steroids or antiseizure medications\n\nHormone receptor status:\n\nNot specified\n\nPATIENT CHARACTERISTICS:\n\nSex\n\nFemale\n\nMenopausal status\n\nNot specified\n\nPerformance status\n\nSWOG 0-2\n\nLife expectancy\n\nNot specified\n\nHematopoietic\n\nAbsolute neutrophil count \u2265 1,500/mm^3\nPlatelet count \u2265 100,000/mm^3\nHemoglobin \u2265 10 g/dL\n\nHepatic\n\nBilirubin \u22643.0 mg/dL\nAST and ALT \u2264 2.5 times upper limit of normal\n\nRenal\n\nCreatinine \u2264 1.5 mg/dL\n\nOther\n\nNot pregnant or nursing\nFertile patients must use effective contraception\nNo serious systemic disorder that would preclude study compliance\nNo history of another malignancy except curatively treated carcinoma of the cervix or basal cell or squamous cell skin cancer in complete remission\nNo unresolved bacterial infection requiring antibiotic treatment\nNo known HIV-1 positivity\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nAt least 3 weeks since prior biologic therapy\n\nChemotherapy\n\nPrior adjuvant chemotherapy allowed\n\nPrior adjuvant or neoadjuvant taxane-based therapy or taxane therapy for metastatic disease allowed\n\nPatient must have failed therapy within 2 years after completion of treatment\nAt least 3 weeks since prior chemotherapy\nNo more than 2 prior cytotoxic chemotherapy regimens for metastatic disease\nNo prior gemcitabine hydrochloride\nNo other concurrent chemotherapy\n\nEndocrine therapy\n\nSee Disease Characteristics\n\nAt least 2 weeks since prior and no concurrent hormonal therapy\n\nMust have documented disease progression during prior hormonal therapy\n\nRadiotherapy\n\nSee Disease Characteristics\nAt least 4 weeks since prior radiotherapy and recovered\nNo concurrent radiotherapy\n\nSurgery\n\nAt least 3 weeks since prior surgery\n\nOther\n\nAt least 3 weeks since prior investigational therapy\n\nAt least 1 week since prior soy supplements (e.g., soy-based pills, liquids, or concentrates)\n\nDietary soy as part of a meal (e.g., tofu) allowed once a week\n\nNo concurrent nutritional supplements, herbal agents, or high doses of antioxidants (e.g., vitamins C, D, or E) that may interact with, antagonize, alter, or imitate the potential effects of gemcitabine hydrochloride or genistein\n\nA single daily multivitamin is allowed\nNo other concurrent immunotherapy\nNo other concurrent experimental medication\nConcurrent anticoagulants, appetite stimulants, and replacement steroids allowed",
                "HealthyVolunteers": "No",
                "Gender": "Female",
                "MinimumAge": "18 Years",
                "MaximumAge": "120 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Amy Weise, DO",
                            "OverallOfficialAffiliation": "Barbara Ann Karmanos Cancer Institute",
                            "OverallOfficialRole": "Principal Investigator"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Barbara Ann Karmanos Cancer Institute",
                            "LocationCity": "Detroit",
                            "LocationState": "Michigan",
                            "LocationZip": "48201-1379",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "ResultsSection": {
            "ParticipantFlowModule": {
                "FlowGroupList": {
                    "FlowGroup": [
                        {
                            "FlowGroupId": "FG000",
                            "FlowGroupTitle": "Gemcitabine, Genistein (Novasoy), Tumor Biopsy",
                            "FlowGroupDescription": "Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.\n\ngenistein: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.\n\ngemcitabine: Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days\n\nTumor biopsy: Biopsy of tumor prior to dose of genistein (Novasoy)"
                        }
                    ]
                },
                "FlowPeriodList": {
                    "FlowPeriod": [
                        {
                            "FlowPeriodTitle": "Overall Study",
                            "FlowMilestoneList": {
                                "FlowMilestone": [
                                    {
                                        "FlowMilestoneType": "STARTED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "19"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "17"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowMilestoneType": "NOT COMPLETED",
                                        "FlowAchievementList": {
                                            "FlowAchievement": [
                                                {
                                                    "FlowAchievementGroupId": "FG000",
                                                    "FlowAchievementNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "FlowDropWithdrawList": {
                                "FlowDropWithdraw": [
                                    {
                                        "FlowDropWithdrawType": "Not response evaluable",
                                        "FlowReasonList": {
                                            "FlowReason": [
                                                {
                                                    "FlowReasonGroupId": "FG000",
                                                    "FlowReasonNumSubjects": "2"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "BaselineCharacteristicsModule": {
                "BaselineGroupList": {
                    "BaselineGroup": [
                        {
                            "BaselineGroupId": "BG000",
                            "BaselineGroupTitle": "Gemcitabine, Genistein (Novasoy), Tumor Biopsy",
                            "BaselineGroupDescription": "Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.\n\ngenistein: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.\n\ngemcitabine: Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days\n\nTumor biopsy: Biopsy of tumor prior to dose of genistein (Novasoy)"
                        }
                    ]
                },
                "BaselineDenomList": {
                    "BaselineDenom": [
                        {
                            "BaselineDenomUnits": "Participants",
                            "BaselineDenomCountList": {
                                "BaselineDenomCount": [
                                    {
                                        "BaselineDenomCountGroupId": "BG000",
                                        "BaselineDenomCountValue": "19"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "BaselineMeasureList": {
                    "BaselineMeasure": [
                        {
                            "BaselineMeasureTitle": "Age, Continuous",
                            "BaselineMeasureParamType": "Median",
                            "BaselineMeasureDispersionType": "Inter-Quartile Range",
                            "BaselineMeasureUnitOfMeasure": "years",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "53",
                                                                "BaselineMeasurementLowerLimit": "31",
                                                                "BaselineMeasurementUpperLimit": "57"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Sex: Female, Male",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "Female",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "19"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Male",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Race (NIH/OMB)",
                            "BaselineMeasureParamType": "Count of Participants",
                            "BaselineMeasureUnitOfMeasure": "Participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Asian",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Black or African American",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "11"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "White",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "8"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "More than one race",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineCategoryTitle": "Unknown or Not Reported",
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        {
                            "BaselineMeasureTitle": "Region of Enrollment",
                            "BaselineMeasureParamType": "Number",
                            "BaselineMeasureUnitOfMeasure": "participants",
                            "BaselineClassList": {
                                "BaselineClass": [
                                    {
                                        "BaselineClassTitle": "United States",
                                        "BaselineCategoryList": {
                                            "BaselineCategory": [
                                                {
                                                    "BaselineMeasurementList": {
                                                        "BaselineMeasurement": [
                                                            {
                                                                "BaselineMeasurementGroupId": "BG000",
                                                                "BaselineMeasurementValue": "19"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "OutcomeMeasuresModule": {
                "OutcomeMeasureList": {
                    "OutcomeMeasure": [
                        {
                            "OutcomeMeasureType": "Primary",
                            "OutcomeMeasureTitle": "Objective Response Rate by RECIST Criteria Following",
                            "OutcomeMeasureDescription": "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.",
                            "OutcomeMeasureReportingStatus": "Posted",
                            "OutcomeMeasureParamType": "Number",
                            "OutcomeMeasureUnitOfMeasure": "participants",
                            "OutcomeMeasureTimeFrame": "every 2 courses until disease progression or death, up to 24 weeks",
                            "OutcomeGroupList": {
                                "OutcomeGroup": [
                                    {
                                        "OutcomeGroupId": "OG000",
                                        "OutcomeGroupTitle": "Gemcitabine & Genistein",
                                        "OutcomeGroupDescription": "Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days."
                                    }
                                ]
                            },
                            "OutcomeDenomList": {
                                "OutcomeDenom": [
                                    {
                                        "OutcomeDenomUnits": "Participants",
                                        "OutcomeDenomCountList": {
                                            "OutcomeDenomCount": [
                                                {
                                                    "OutcomeDenomCountGroupId": "OG000",
                                                    "OutcomeDenomCountValue": "17"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OutcomeClassList": {
                                "OutcomeClass": [
                                    {
                                        "OutcomeCategoryList": {
                                            "OutcomeCategory": [
                                                {
                                                    "OutcomeMeasurementList": {
                                                        "OutcomeMeasurement": [
                                                            {
                                                                "OutcomeMeasurementGroupId": "OG000",
                                                                "OutcomeMeasurementValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "AdverseEventsModule": {
                "EventsFrequencyThreshold": "5",
                "EventGroupList": {
                    "EventGroup": [
                        {
                            "EventGroupId": "EG000",
                            "EventGroupTitle": "Gemcitabine & Genistein",
                            "EventGroupDescription": "Gemcitabine, genistein (Novasoy), Tumor biopsy Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.",
                            "EventGroupSeriousNumAffected": "5",
                            "EventGroupSeriousNumAtRisk": "19",
                            "EventGroupOtherNumAffected": "2",
                            "EventGroupOtherNumAtRisk": "19"
                        }
                    ]
                },
                "SeriousEventList": {
                    "SeriousEvent": [
                        {
                            "SeriousEventTerm": "White blood cells (WBC)",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "5",
                                        "SeriousEventStatsNumAffected": "5",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Hemoglobin (Hgb)",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Absolute neutrophil count (ANC)",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "5",
                                        "SeriousEventStatsNumAffected": "5",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Platelets",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Elevated Aspartate Aminotransferase (AST)",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Elevated Alanine Aminotransferase (ALT)",
                            "SeriousEventOrganSystem": "Investigations",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "1",
                                        "SeriousEventStatsNumAffected": "1",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Pain",
                            "SeriousEventOrganSystem": "General disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "SeriousEventTerm": "Dyspnea",
                            "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                            "SeriousEventSourceVocabulary": "CTCAE (3.0)",
                            "SeriousEventAssessmentType": "Systematic Assessment",
                            "SeriousEventStatsList": {
                                "SeriousEventStats": [
                                    {
                                        "SeriousEventStatsGroupId": "EG000",
                                        "SeriousEventStatsNumEvents": "3",
                                        "SeriousEventStatsNumAffected": "3",
                                        "SeriousEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        }
                    ]
                },
                "OtherEventList": {
                    "OtherEvent": [
                        {
                            "OtherEventTerm": "Hemoglobin (Hgb)",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Platelets",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Fatigue",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Vomiting",
                            "OtherEventOrganSystem": "Gastrointestinal disorders",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Elevated Alkaline Phosphate",
                            "OtherEventOrganSystem": "Investigations",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Pain",
                            "OtherEventOrganSystem": "General disorders",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "2",
                                        "OtherEventStatsNumAffected": "2",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Hot flashes",
                            "OtherEventOrganSystem": "Vascular disorders",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        },
                        {
                            "OtherEventTerm": "Rash",
                            "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                            "OtherEventSourceVocabulary": "CTCAE (3.0)",
                            "OtherEventAssessmentType": "Systematic Assessment",
                            "OtherEventStatsList": {
                                "OtherEventStats": [
                                    {
                                        "OtherEventStatsGroupId": "EG000",
                                        "OtherEventStatsNumEvents": "1",
                                        "OtherEventStatsNumAffected": "1",
                                        "OtherEventStatsNumAtRisk": "19"
                                    }
                                ]
                            }
                        }
                    ]
                }
            },
            "MoreInfoModule": {
                "CertainAgreement": {
                    "AgreementPISponsorEmployee": "Yes"
                },
                "PointOfContact": {
                    "PointOfContactTitle": "Amy Weise, M.D.",
                    "PointOfContactOrganization": "Barbara Ann Karmanos Cancer Institute",
                    "PointOfContactEMail": "weisea@karmanos.org",
                    "PointOfContactPhone": "313-576-8599"
                }
            }
        },
        "DocumentSection": {
            "LargeDocumentModule": {
                "LargeDocList": {
                    "LargeDoc": [
                        {
                            "LargeDocTypeAbbrev": "Prot_SAP",
                            "LargeDocHasProtocol": "Yes",
                            "LargeDocHasSAP": "Yes",
                            "LargeDocHasICF": "No",
                            "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                            "LargeDocDate": "January 9, 2009",
                            "LargeDocUploadDate": "06/15/2022 10:25",
                            "LargeDocFilename": "Prot_SAP_000.pdf"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000093542",
                            "InterventionMeshTerm": "Gemcitabine"
                        },
                        {
                            "InterventionMeshId": "D000019833",
                            "InterventionMeshTerm": "Genistein"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000964",
                            "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000963",
                            "InterventionAncestorTerm": "Antimetabolites"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000016588",
                            "InterventionAncestorTerm": "Anticarcinogenic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000020011",
                            "InterventionAncestorTerm": "Protective Agents"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000047428",
                            "InterventionAncestorTerm": "Protein Kinase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000048789",
                            "InterventionAncestorTerm": "Phytoestrogens"
                        },
                        {
                            "InterventionAncestorId": "D000004968",
                            "InterventionAncestorTerm": "Estrogens, Non-Steroidal"
                        },
                        {
                            "InterventionAncestorId": "D000004967",
                            "InterventionAncestorTerm": "Estrogens"
                        },
                        {
                            "InterventionAncestorId": "D000006728",
                            "InterventionAncestorTerm": "Hormones"
                        },
                        {
                            "InterventionAncestorId": "D000006730",
                            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M2986",
                            "InterventionBrowseLeafName": "Gemcitabine",
                            "InterventionBrowseLeafAsFound": "Mg/kg",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M21411",
                            "InterventionBrowseLeafName": "Genistein",
                            "InterventionBrowseLeafAsFound": "Intermittent Fasting",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M3971",
                            "InterventionBrowseLeafName": "Antimetabolites",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M21559",
                            "InterventionBrowseLeafName": "Protective Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25510",
                            "InterventionBrowseLeafName": "Protein Kinase Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M25685",
                            "InterventionBrowseLeafName": "Phytoestrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7806",
                            "InterventionBrowseLeafName": "Estrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9478",
                            "InterventionBrowseLeafName": "Hormone Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        }
                    ]
                }
            }
        }
    }
}